Johnson & Johnson Overview
Johnson & Johnson was founded in January 1886 in New Brunswick, New Jersey, by three brothers, Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, after Robert heard a speech by antiseptic-surgery advocate Joseph Lister and saw an opportunity to mass-produce ready-to-use sterile surgical dressings, a category that barely existed at the time. The company began with 14 employees (eight women and six men) in a former factory on Neilson Street, and its first major commercial breakthrough came in 1891 with the first mass-produced first aid kit, originally designed for railroad workers. Robert Wood Johnson served as first president; the company remained privately held by the family until its first public stock offering in 1944.
Learn More Show Less
The company’s defining internal document arrived in 1943, when Robert Wood Johnson II, the founder’s son and then chairman, formalised decades of informal company philosophy into ‘Our Credo’, a one-page statement ranking Johnson & Johnson’s responsibilities in explicit order: first to patients, doctors and nurses; then to employees; then to the communities in which it operates; and only then to shareholders. Still described by the company as a ‘living document’ reviewed periodically but structurally unchanged, the Credo would be tested nearly 40 years later in the defining crisis of Johnson & Johnson’s history. In September 1982, seven people in the Chicago area died after taking Extra-Strength Tylenol capsules that had been laced with cyanide by an unknown party after leaving the factory. Acting against advice from the FBI and business consultants, who argued the contamination was likely confined to a small area, then-CEO James Burke ordered a full national recall of roughly 31 million bottles, worth over $100 million, and offered free replacement product in tamper-resistant packaging. Burke later credited the Credo directly with giving him ‘the ammunition I needed to persuade shareholders’ to accept the cost. The response is still taught in business schools today as the definitive case study in crisis management, and Tylenol not only survived the crisis but recovered its market share within about a year.
Corporately, Johnson & Johnson has restructured substantially in recent years. In 2023, the company completed the spin-off of its consumer health division, home to household names including Band-Aid, Listerine, Aveeno, Neutrogena and Johnson’s Baby, into a new standalone public company called Kenvue, with a separate brand identity also designed by agency Wolff Olins. That separation let the remaining Johnson & Johnson refocus entirely on Innovative Medicine and MedTech. By fiscal year 2025, the streamlined Johnson & Johnson reported $94.19 billion in revenue and around 138,200 employees, and remains, alongside Microsoft, one of only two US-based companies to hold a AAA credit rating from S&P Global.
The Kenvue separation also gave Johnson & Johnson the occasion for its own century-defining rebrand. For more than 135 years, from 1886 until September 2023, the company’s identity centred on a flowing red script based directly on co-founder James Wood Johnson’s actual handwritten signature, visible on the company’s first official cheque in 1886 and refined in 1936 for clearer, more consistent reproduction across packaging and print while keeping its warm, personal character. Announced on 14 September 2023 and designed by branding consultancy Wolff Olins, the new identity replaced that script entirely with a custom, geometric sans-serif wordmark in a brighter red, keeping the ampersand and the absence of word-spacing as the only visual threads back to the old mark. The company framed the change around clarity, digital legibility and a decisive pivot away from consumer products; commentators were split, some praising the modernisation, others lamenting the loss of one of the world’s longest-running corporate marks, with Creative Bloq comparing the decision to Coca-Cola abandoning its own script.
Colour has stayed the one constant across every era: a signature red, refreshed for the 2023 identity to a brighter, more contemporary shade (#D71500) intended to signal urgency and energy alongside the brand’s long-standing associations with care and trust. Typography now centres on a bespoke sans-serif, drawn with smooth, rounded edges and open counters specifically to retain a sense of warmth and humanity the company felt the old script’s replacement risked losing, alongside a redesigned ampersand described internally as a symbol of the company’s ‘caring and connected’ character.
Tone of voice, per the 2023 identity, aims to balance scientific credibility with warmth: clear, inclusive and jargon-light language intended to build trust and confidence with patients, healthcare professionals and partners alike, while still conveying the urgency and progress the company associates with tackling major global health challenges. Johnson & Johnson’s public brand guidelines remain limited; unlike NHS or Duolingo, the full internal system is not published, so much of what’s known about its detailed application comes from press coverage of the 2023 launch rather than a complete public reference.
The clearest lesson in Johnson & Johnson’s brand history is that a written statement of values, if it’s genuinely acted on under real pressure, can outlast any single visual identity. The 1943 Credo, not the 137-year-old script logo, is what actually earned Johnson & Johnson its reputation for trust; the 2023 rebrand changed almost everything visible about the company while leaving that underlying document, and the priority order it sets out, completely untouched.
